NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final ...
Another point of concern for BofA Securities is the potential impact of the upcoming Kisqali patent litigation outcome. Should the decision fall unfavorably for Novartis, it could lead to a ...
Are you looking for Microsoft Store in: {0}?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback